Can hepatocellular carcinoma recurrence be prevented after liver transplantation?

키워드

참고문헌 (10)

1. Jong Man Kim, "Outcomes after Liver Transplantation in Korea: Incidence and Risk Factors from Korean Transplantation Registry", Clinical and Molecular Hepatology, 27(3), pp.451~462 (2021), 대한간학회[DOI]
2. Fernandez-Sevilla E, "Recurrence of hepatocellular carcinoma after liver transplantation : is there a place for resection?", Liver Transpl, 23, pp.440~447 (2017)
3. Minjeong Kim, "Risk factors for poor survival after recurrence of hepatocellular carcinoma after liver transplantation", Annals of Surgical Treatment and Research, 101(1), pp.28~36 (2021), 대한외과학회
4. Bhat M, "Immunosuppression, race, and donor-related risk factors affect de novo cancer incidence across solid organ transplant recipients", Mayo Clin Proc, 93, pp.1236~1246 (2018)
5. Incheon Kang, "Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma", Clinical and Molecular Hepatology, 27(4), pp.589~602 (2021), 대한간학회[DOI]
6. Yee ML, "Use of everolimus in liver transplantation", World J Hepatol, 9, pp.990~1000 (2017)
7. Toso C, "Sirolimusbased immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma", Hepatology, 51, pp.1237~1243 (2010)
8. Geissler EK, "Sirolimus use in liver transplant recipients with hepatocellular carcinoma : a randomized, multicenter, open-label phase 3trial", Transplantation, 100, pp.116~125 (2016)
9. Lee SG, "Efficacy and safety of everolimus with reduced tacrolimus in liver transplant recipients : 24-month results from the pooled analysis of 2randomized controlled trials", Transplantation, 105, pp.1564~1575 (2021)
10. Schnitzbauer AA, "mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors", Ann Surg, 272, pp.855~862 (2020)

관련 논문AI추천